Wonbi-D, the long-awaited product that placed IL-YANG PHARM on solid foundations today, was lunched on June 16, 1971. We built Neusilin composition plant in Yongin in November 1972, went through business opening in 1742 and became the 125th listed company in Korea. Entering the 1980's, IL-YANG repeated its rapid growth. Then we set up branch offices in Hong Kong and Singapore, and exported 20 kinds of pharmaceutical raw material and finished products to 14 countries. Successfully modernizing production facilities by building up organic raw material composition plant in 1983 and GMP plant in 1985, we released 'Ganoderma Lucidum Youngbichun Drink' the same year. In 1990's, we actively developed new medicine and invested considerable profits from Wonbi-D and Youngbichun in a search for epoch-making cures and new medicine development.

Our vaccine plant, built upon the premise of 89,256㎡ and gross floor area of 13,361㎡, founded a flu vaccine production line to manufacture 60 million doses per year. Securing high-quality, efficient fertile eggs, we will take form of pre-incubation in GMP plant and put forth all our efforts to manufacture highly stable vaccine. Our plant, one of our best growth engines, is aiming to sell products in 2013 and produce advanced undiluted vaccine solution with up-to-date production facilities to guarantee smooth supply and overseas export to underprivileged countries.

IL-YANG BIOPHARM, a noted pharmaceutical company under the slogan of "Value Creation with Respect for Man's Life and Dignity", is aiming to invest in pharmaceutical raw material, finished product, food industry, and bio-field and be a comprehensive drug company. Furnished with state-of-the-art production facilities of cGMP standards, it has varied ETC-based production lines for Noltec, a future generation's antiulcer medicine and 'Supect', a super leukemia medicine, and is planning to advance into bigger market with expansion of amount of materials under OEM.